|Videos|April 19, 2017

Efficacy Results of ARIEL2 Trial in Ovarian Cancer

Elizabeth Swisher, MD, discusses the results of the ARIEL2 trial in patients in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a germline or somatic BRCA mutation.

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the results of the ARIEL2 trial in patients in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a germline or somaticBRCA

Stay up to date on practice-changing data in community practice.

Related to this article

November 13th, 2026

Dr Parikh on the Future of Oncology: AI, Data, and Patients at the Center

Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.

November 12th, 2026

Dr Iyer on AI Documentation and Tumor Boards in Neuroendocrine Tumors

Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.

November 12th, 2026

Dr Chauhan on DLL3 Expression and Obrixtamig Outcomes in DAREON-7

Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.

November 12th, 2026

DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC

Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.

November 9th, 2026

Dr Iyer on Digitizing NCCN Guidelines for AI at the Point of Care

Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.